Updated Jul 16, 2026
Burrows Scott L has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $4.16M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 1.7K | $88.37 | $152K |
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 5.8K | $87.55 | $506K |
| 2026-07-03 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise | 7.5K | $14.50 | $109K |
| 2026-06-27 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 10.0K | $87.14 | $871K |
| 2026-06-27 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 5.0K | $87.12 | $436K |
| 2026-06-27 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise | 15.0K | $14.50 | $218K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 3.1K | $72.06 | $223K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 2.6K | $70.77 | $184K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 1.8K | $69.75 | $126K |
| 2026-06-04 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise | 7.5K | $14.50 | $109K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 12.5K | $71.37 | $892K |
| 2026-05-02 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise | 12.5K | $14.50 | $181K |
| 2026-04-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.3K | $49.98 | $65K |
| 2026-04-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.2K | $49.21 | $305K |
| 2026-04-04 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise [10b5-1] | 7.5K | $14.50 | $109K |
| 2026-03-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 200 | $41.66 | $8K |
| 2026-03-04 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.3K | $40.56 | $93K |
| 2026-03-04 | SYRE | Spyre Therapeutics, Inc. | M — Option exercise [10b5-1] | 2.5K | $14.50 | $36K |
| 2025-09-02 | SYRE | Spyre Therapeutics, Inc. | S — Open-market sale | 18.4K | $16.26 | $300K |
Burrows Scott L is a corporate insider — currently tracked as Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha tracks every SEC Form 4 filing in real time.
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($4.16M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Burrows Scott L profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.